Skip to content

Target Fortification of Breast Milk: How Often Breast Milk Needs to be Measured?

Target Fortification of Breast Milk: The Effect of Different Schedules for Milk Analysis on the Growth and Development of Preterm Infants.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02865941
Acronym
TFO2
Enrollment
56
Registered
2016-08-15
Start date
2016-09-30
Completion date
2019-06-30
Last updated
2016-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postnatal Growth Disorder

Keywords

Target Fortification, Breast milk analysis, Nutrition, Macronutrient intake, Protein accretion

Brief summary

It has been observed that target fortification on different schedules leads to meal to meal variation. It changes the ratio of protein to energy and the percentage of carbohydrate to non-protein energy which may, affect growth. In the past, the investigators have analyzed the outcomes of breast milk composition when target fortification is done with different analysis schedules. The investigators were able to measure the macronutrient intake for different milk analysis schedules via a theoretical model and show that the more frequent schedules reduce the variation of fortified-breast milk, whereas a reduced schedule leads to a high variation of macronutrients. It was observed that, in all the breast milk samples measured twice per week, infants achieved on average the recommended macronutrients in line with current recommendations. Nonetheless, the model only looks at the macronutrient intake and does not investigates the relationship between macronutrient variation and its effect on growth. The aim of the current study is to compare a frequent schedule of measurement of macronutrient analysis with a reduced schedule of measurement and to study its affect on growth, protein accretion and metabolic parameter.

Interventions

DIETARY_SUPPLEMENTFortification with modular carbohydrate

Modular product supplementation is based on most recent breast analysis done for the participant.

DIETARY_SUPPLEMENTFortification with modular protein

Modular product supplementation is based on most recent breast analysis done for the participant.

DIETARY_SUPPLEMENTFortification with modular fat

Modular product supplementation is based on most recent breast analysis done for the participant.

Sponsors

McMaster Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
No minimum to 29 Weeks
Healthy volunteers
No

Inclusion criteria

1. Gestational age \< 30 weeks (maternal dates or early fetal ultrasound); 2. Tolerating an enteral intake of ≥100 mL/kg/d for ≥ 24h; 3. Subject is anticipated to receive the intervention for ≥ 3 consecutive weeks after full enteral feeding (≥150 mL/kg/d) has been achieved; 4. Written informed consent has been obtained from the infant's legal representative. 5. Multiple births: Each infant will be included in the study if he/she meets the study criteria, and siblings will be individually randomized to one or other of the treatment arms. 6. Discussion with Most Responsible Physician (MRP) and the staff in order to discuss any potential transfer during the next 7 days.

Exclusion criteria

1. Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities; 2. Babies with enterostoma or short gut syndrome; 3. Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk; 4. Fluid restriction \<140 mL/kg/d for ≥ 3 consecutive days; 5. Sepsis - all infants with gram-negative sepsis will be removed from the study; 6. Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3); 7. Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen \>10 mmol/L and creatinine of 130mmol/L 8. Participation in another clinical trial that may provide an alternative nutritional intervention, which might affect the outcomes of this study. outcomes of this study; 9. Probability of transfer to another neonatal intensive care unit or level II nursery outside the McMaster Children's Hospital, as discussed with the most responsible physician (MRP)

Design outcomes

Primary

MeasureTime frame
Growth during first three weeks of interventionfirst three weeks during intervention before 36 weeks of gestation

Secondary

MeasureTime frameDescription
Weight Gainfrom inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
Oxidative stress by 8-Oxo-2'-deoxyguanosine metabolites in urinefrom inclusion at postmenstrual age <30 weeks until dischargeMeasured by mass spectroscopy
Protein synthesis analyzed by nitrogen excretion in urine [µmol/mL]first three weeks during intervention before 36 weeks of gestation
Feeding intolerance questionairefrom inclusion at postmenstrual age <30 weeks until dischargevolume of gastric residuals, color of gastric residuals, vomiting, abdominal girth, abdominal distention
Daily Nutrient intake (kcal, lactose, protein, fat) measured with conventional milk analysisfrom inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
Lean mass [g]from inclusion at postmenstrual age <30 weeks until dischargeMeasured with bioelectrical impedance analysis
Head circumference [cm]from inclusion at postmenstrual age <30 weeks until dischargeMeasured by tape
Body length [cm]from inclusion at postmenstrual age <30 weeks until dischargeMeasured by length board
Fat mass [g]from inclusion at postmenstrual age <30 weeks until dischargeMeasured with bioelectrical impedance analysis

Countries

Canada

Contacts

Primary ContactChristoph Fusch, MD, PhD
fusch@mcmaster.ca+1 521 2100
Backup ContactNiels Rochow, MD
rochow@mcmaster.ca+1 521 2100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026